Ignite Creation Date:
2025-12-25 @ 4:51 AM
Ignite Modification Date:
2026-03-02 @ 4:55 PM
Study NCT ID:
NCT02142218
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2016-09-29
First Post:
2014-05-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Program With Nivolumab to Treat Melanoma
Sponsor:
Bristol-Myers Squibb
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Stage III (Unresectable) or Stage IV Advanced Melanoma | View |
Keywords: